A Study to Evaluate Setanaxib in Patients With Alport Syndrome

Clinical trial NCT06274489 · COMPLETED

Trial details

NCT number: NCT06274489
Sponsor: Calliditas Therapeutics AB
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Alport Syndrome

Start date: 2023-11-27
Primary completion: 2025-06-24
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.